Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Nxera Pharma UK Limited
- Target Recruit Count
- 33
- Registration Number
- NCT04941989
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution
- Conditions
- Healthy Subjects
- Interventions
- Drug: HTL0016878.Citrate Capsule 10 mgDrug: HTL0016878.HCl Solution 10 mg
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Nxera Pharma UK Limited
- Target Recruit Count
- 15
- Registration Number
- NCT04935320
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd (HMR), London, United Kingdom
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Nxera Pharma UK Limited
- Target Recruit Count
- 42
- Registration Number
- NCT03847207
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
News
Tempero Bio Secures $70M Series B to Advance Novel Addiction Treatment Through Phase 2 Trials
Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials.
Verily and Sosei Heptares Achieve Early Success in AI-Powered GPCR Drug Discovery for Autoimmune Diseases
Verily's Immune Profiler platform has successfully identified novel GPCR targets for autoimmune diseases within six months of launching collaboration with Sosei Heptares.
Boehringer Ingelheim Expands Schizophrenia Pipeline with Sosei Heptares and Autifony Collaborations
Boehringer Ingelheim licenses GPR52 agonists from Sosei Heptares for €755m, targeting a range of schizophrenia symptoms including positive, negative, and cognitive dysfunction.
Genentech Expands Drug Discovery Portfolio with Three Strategic Platform Partnerships
Genentech has secured partnerships with Convelo Therapeutics, Sosei Heptares, and Skyhawk Therapeutics to enhance its small-molecule drug discovery capabilities across multiple therapeutic areas.